期刊
NEUROSCIENCE LETTERS
卷 655, 期 -, 页码 90-94出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.neulet.2017.06.034
关键词
alpha-Synuclein; O-GIcNAcylation; Aggregation; SDS-resistant oligomers
资金
- National High-tech RD Program [2015AA020502]
- National Natural Science Foundation of China [31371187]
- Key Research and Development Program of Hunan Province [2016DK2005]
Neurodegenerative diseases including dementia with Lewy bodies, Lewy body variant of Alzheimer's disease, and Parkinson's disease are associated with the aberrant aggregation of alpha-synuclein, which is influenced by several post-translational modifications (PTM5). O-GlcNAcylation is one PTM that has an important role in many fundamental processes. The O-GlcNAcylation of endogenous a-synuclein at residues 53, 64, 72 and 87 has been reported in an unbiased mass spectrum analysis. The consequences of O-GlcNAcylation at residues 72 or 87 have been studied by using a synthetic a-synuclein bearing O-GlcNAcylation at threonine residue 72 or serine 87, respectively. O-GlcNAcylation at Thr72 or Ser87 suppresses the aggregation of alpha-synuclein. However, the effect of enzymatic O-GlcNAcylation of otsynuclein at multiple residues is not clear. Here, we successfully generated O-GlcNAcylated alpha-synuclein by co-expressing a shorter form of OGT (sOGT) with a-synuclein. The O-GlcNAcylation inhibited asynuclein aggregation and promoted the formation of soluble SDS-resistant and Thioflavine T negative oligomers. Our data warrant further studies on the role of O-GlcNAcylation in the progression/treatment of Parkinson's disease in animal models. (C) 2017 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据